Related references
Note: Only part of the references are listed.Jagged1-mediated myeloid Notch1 signaling activates HSF1/Snail and controls NLRP3 inflammasome activation in liver inflammatory injury
Yuting Jin et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors
Jessica M. Konen et al.
CELLS (2020)
Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
Sadal Refae et al.
SCIENTIFIC REPORTS (2020)
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy
Balamayoora Theivanthiran et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer
Baptiste Kas et al.
JAMA ONCOLOGY (2020)
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S. Grasso et al.
CANCER CELL (2020)
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Giuseppe Lamberti et al.
CANCERS (2020)
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
Giuseppe Lamberti et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities
Yada Kanjanapan et al.
CANCER (2019)
Cognate Nonlytic Interactions between CD8+ T Cells and Breast Cancer Cells Induce Cancer Stem Cell-like Properties
Roland G. Stein et al.
CANCER RESEARCH (2019)
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Giuseppe Lo Russo et al.
CLINICAL CANCER RESEARCH (2019)
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
Chien-Chun Steven Pai et al.
IMMUNITY (2019)
Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report
Ilke Tunali et al.
LUNG CANCER (2019)
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
Geoffrey T. Gibney et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
C. G. Kim et al.
ANNALS OF ONCOLOGY (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases
Kelly A. Hogan et al.
FRONTIERS IN IMMUNOLOGY (2019)
Ischemia Is Related to Tumour Genetics in Uveal Melanoma
Niels J. Brouwer et al.
CANCERS (2019)
Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor
Zihan Xu et al.
ONCOTARGETS AND THERAPY (2019)
Pharmacological inhibition of Notch signaling regresses pre- established abdominal aortic aneurysm
Neekun Sharma et al.
SCIENTIFIC REPORTS (2019)
Novel patterns of response under immunotherapy
E. Borcoman et al.
ANNALS OF ONCOLOGY (2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A. Davis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Thomas G. Martin et al.
CELLS (2019)
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
Akinori Sasaki et al.
GASTRIC CANCER (2019)
CD38 affects the biological behavior and energy metabolism of nasopharyngeal carcinoma cells
Yanshan Ge et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer
Masahiko Aoki et al.
ESMO OPEN (2019)
Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary roundtable discussion
Anna S. Berghoff et al.
ESMO OPEN (2019)
The Dark Side of IFN-: Its Role in Promoting Cancer Immunoevasion
Marija Mojic et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer
Mohammad H. Kazemi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Toll-like receptor 2 ligand and interferon-gamma suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells
Hiroaki Shime et al.
ONCOIMMUNOLOGY (2018)
The binding of an anti-PD-1 antibody to FcγRI has a profound impact on its biological functions
Tong Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
CD38-NAD(+)Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
Shilpak Chatterjee et al.
CELL METABOLISM (2018)
Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells
Bertram Bengsch et al.
IMMUNITY (2018)
Regulation of the Immune Response by the Aryl Hydrocarbon Receptor
Cristina Gutierrez-Vazquez et al.
IMMUNITY (2018)
Paracrine Wnt5a-beta-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization
Fei Zhao et al.
IMMUNITY (2018)
The Crosstalk between Nrf2 and Inflammasomes
Paulina Hennig et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2018)
Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy
Lee Ratner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genetic association study of NLRP1, CARD, and CASP1 inflammasome genes with chronic Chagas cardiomyopathy among Trypanosoma cruzi seropositive patients in Bolivia
Steven J. Clipman et al.
PLOS ONE (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Limo Chen et al.
CANCER DISCOVERY (2018)
Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
Marjorie Faure et al.
FRONTIERS IN IMMUNOLOGY (2018)
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Rebekka Weber et al.
FRONTIERS IN IMMUNOLOGY (2018)
The Role of indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
Lilla Hornyak et al.
FRONTIERS IN IMMUNOLOGY (2018)
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Flavia Castro et al.
FRONTIERS IN IMMUNOLOGY (2018)
Blockade of Tumor-Expressed PD-1 promotes lung cancer growth
Shisuo Du et al.
ONCOIMMUNOLOGY (2018)
Detailed analysis of adenosine A2a receptor (ADORA2A) and CD73 (5'-nucleotidase, ecto, NT5E) methylation and gene expression in head and neck squamous cell carcinoma patients
Timo J. Vogt et al.
ONCOIMMUNOLOGY (2018)
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials.
Ignacio Matos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Clinicopathological, genomic and immunological features of hyperprogressive disease during PD-1 blockade in gastric cancer patients.
Yosuke Togashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeting the IDO1 pathway in cancer: from bench to bedside
Ming Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Andrea Botticelli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi et al.
MOLECULAR CANCER (2018)
Cancer Cell-intrinsic PD-1 and implications in Combinatorial immunotherapy
Han Yao et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
Niels W. C. J. van de Donk et al.
FRONTIERS IN IMMUNOLOGY (2018)
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara et al.
JAMA ONCOLOGY (2018)
Targeting Adenosine Receptor Signaling in Cancer Immunotherapy
Kevin Sek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma
James J. Hsieh et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells
Xiangning Bu et al.
CARCINOGENESIS (2018)
Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
Donghai Xiong et al.
ISCIENCE (2018)
Considerations for successful cancer immunotherapy in aged hosts
V. Hurez et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Stephane Champiat et al.
CLINICAL CANCER RESEARCH (2017)
Delphinidin inhibits angiogenesis through the suppression of HIF-1α and VEGF expression in A549 lung cancer cells
Mun-Hyeon Kim et al.
ONCOLOGY REPORTS (2017)
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Xinqi Wu et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
Ruea-Yea Huang et al.
ONCOIMMUNOLOGY (2017)
Blockade of Notch signaling promotes acetaminophen-induced liver injury
Longfeng Jiang et al.
IMMUNOLOGIC RESEARCH (2017)
Targeting A2 adenosine receptors in cancer
David Allard et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade
Esra A. Akbay et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma
Si-Rui Ma et al.
MOLECULAR CANCER (2017)
CD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions
Shan Liao et al.
MOLECULAR CARCINOGENESIS (2017)
PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
Tim Wartewig et al.
NATURE (2017)
CANCER IMMUNOTHERAPY The dark side of PD-1 receptor inhibition
Aye Ludin et al.
NATURE (2017)
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
Thomas Kammertoens et al.
NATURE (2017)
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T. Manguso et al.
NATURE (2017)
Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
Y. Liu et al.
ONCOGENE (2017)
Chemotherapy regimen based on sorafenib combined with 5-FU on HIF-1α and VEGF expression and survival in advanced gastric cancer patients
Ronghui Cheng et al.
ONCOLOGY LETTERS (2017)
Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression
Chongbiao Huang et al.
NATURE COMMUNICATIONS (2017)
P53 prevent tumor invasion and metastasis by down-regulating IDO in lung cancer
Dongfang Tang et al.
ONCOTARGET (2017)
IL-35 induces N2 phenotype of neutrophils to promote tumor growth
Jiu-Ming Zou et al.
ONCOTARGET (2017)
PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
Maria Gato-Canas et al.
CELL REPORTS (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance
Marc Hennequart et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455
Stefania Gessi et al.
FRONTIERS IN PHARMACOLOGY (2017)
Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future
Emma C. Fields et al.
FRONTIERS IN ONCOLOGY (2017)
Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.
Raymond P. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Targeting immunosuppressive adenosine in cancer
D. Vijayan et al.
NATURE REVIEWS CANCER (2017)
IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer
Purushottam Lamichhane et al.
CANCER RESEARCH (2017)
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
Xiaoyan Feng et al.
CLINICAL CANCER RESEARCH (2017)
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
E. Saada-Bouzid et al.
ANNALS OF ONCOLOGY (2017)
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Abigail E. Overacre-Delgoffe et al.
CELL (2017)
NOX2-ROS-HIF-1α signaling is critical for the inhibitory effect of oleanolic acid on rectal cancer cell proliferation
Yongfeng Guo et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects
Abdulla A-B Badawy
INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH (2017)
Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer
Zhonghua Zhao et al.
CYTOKINE (2017)
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors
M. Ahamadi et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
H. Jiang et al.
LEUKEMIA (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
Curtis A. Clark et al.
CANCER RESEARCH (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Almut Brand et al.
Cell Metabolism (2016)
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Alexander Martens et al.
CLINICAL CANCER RESEARCH (2016)
Clinical Significance of Circulating CD33+ CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
Moshe Sade-Feldman et al.
CLINICAL CANCER RESEARCH (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
Marco De Simone et al.
IMMUNITY (2016)
NOTCH SIGNAL REGULATES INFLAMMASOME NLRP3 ACTIVATION IN LIVER ISCHEMIA AND REPERFUSION INJURY
S. Yue et al.
JOURNAL OF HEPATOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Specific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage Infiltration
Patrycja Koszalka et al.
PLOS ONE (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia-Wei Li et al.
NATURE COMMUNICATIONS (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
Francesco Passiglia et al.
ONCOTARGET (2016)
F-actin dampens NLRP3 inflammasome activity via Flightless-I and LRRFIP2
Danielle Burger et al.
SCIENTIFIC REPORTS (2016)
Selection, Analysis and Improvement of Anti-Angiogenesis Compounds Identified by an Anti-HIF-1α Screening and Validation System
Chikezie Madu et al.
JOURNAL OF CANCER (2016)
PD-1 marks dysfunctional regulatory T cells in malignant gliomas
Daniel E. Lowther et al.
JCI INSIGHT (2016)
Purinergic regulation of the immune system
Caglar Cekic et al.
NATURE REVIEWS IMMUNOLOGY (2016)
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells
Z. Sun et al.
CANCER RESEARCH (2015)
CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer
Tatiana A. Karakasheva et al.
CANCER RESEARCH (2015)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang et al.
CELL (2015)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel et al.
CELL (2015)
Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
IL-27 induces the expression of IDO and PD-L1 in human cancer cells
Grazia Carbotti et al.
ONCOTARGET (2015)
Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy
Alisha Holtzhausen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
Robert D. Leone et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2015)
Chronic Lymphocytic Leukemia Cells Express CD38 in Response to Th1 Cell-Derived IFN-γ by a T-bet-Dependent Mechanism
Simone Burgler et al.
JOURNAL OF IMMUNOLOGY (2015)
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance
Sahitya K. Denduluri et al.
GENES & DISEASES (2015)
Interferon-γ produced by tumor-infiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells
Yi Lu et al.
ANGIOGENESIS (2014)
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Christiane Meyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1-or Melan-A-Specific T Cells
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2014)
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert et al.
CLINICAL CANCER RESEARCH (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
CARD8 is a negative regulator for NLRP3 inflammasome, but mutant NLRP3 in cryopyrin-associated periodic syndromes escapes the restriction
Sayaka Ito et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth
Wiebke Hansen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
IFN-γ Production by Allogeneic Foxp3+ Regulatory T Cells Is Essential for Preventing Experimental Graft-versus-Host Disease
Christian Koenecke et al.
JOURNAL OF IMMUNOLOGY (2012)
Autocrine IFN-γ Promotes Naive CD8 T Cell Differentiation and Synergizes with IFN-α To Stimulate Strong Function
Julie M. Curtsinger et al.
JOURNAL OF IMMUNOLOGY (2012)
PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer
John Dulos et al.
JOURNAL OF IMMUNOTHERAPY (2012)
CD38 deficiency in the tumor microenvironment attenuates glioma progression and modulates features of tumor-associated microglia/macrophages
Ayelet Levy et al.
NEURO-ONCOLOGY (2012)
Autocrine functions of VEGF in breast tumor cells Adhesion, survival, migration and invasion
Martine Perrot-Applanat et al.
CELL ADHESION & MIGRATION (2012)
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR A novel IDO effector pathway targeted by D-1-methyl-tryptophan
Richard Metz et al.
ONCOIMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Angiopoietin-2 promotes myeloid cell infiltration in a β2-integrin-dependent manner
Alexander Scholz et al.
BLOOD (2011)
Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer
Dylan M. Glubb et al.
CLINICAL CANCER RESEARCH (2011)
Interleukin-12 Converts Foxp3+ Regulatory T Cells to Interferon-γ-Producing Foxp3+ T Cells That Inhibit Colitis
Ting Feng et al.
GASTROENTEROLOGY (2011)
Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice
Dominik Jauch et al.
GUT (2011)
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Maria T. Pallotta et al.
NATURE IMMUNOLOGY (2011)
Absence of CD38 delays arrival of neutrophils to the liver and innate immune response development during hepatic amoebiasis by Entamoeba histolytica
L. A. Estrada-Figueroa et al.
PARASITE IMMUNOLOGY (2011)
Anti-Inflammatory and Immunosuppressive Effects of the A2A Adenosine Receptor
Gillian R. Milne et al.
THESCIENTIFICWORLDJOURNAL (2011)
Aging, Immunity, and Cancer
Tamas Fulop et al.
DISCOVERY MEDICINE (2011)
IFN-gamma Triggered STAT1-PKB/AKT Signalling Pathway Influences the Function of Alloantigen Reactive Regulatory T Cells
B. Wei et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features
F. Vrbacky et al.
HEMATOLOGY (2010)
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Joshua D. Mezrich et al.
JOURNAL OF IMMUNOLOGY (2010)
CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells
T. Vaisitti et al.
LEUKEMIA (2010)
Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer
Aaron S. Mansfield et al.
BMC CANCER (2009)
The VHL Tumor Suppressor: Master Regulator of HIF
Volker H. Haase
CURRENT PHARMACEUTICAL DESIGN (2009)
Myeloid-derived suppressor cell activation by combined LPS and IFN-γ treatment impairs DC development
Verena Greifenberg et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
IFN Regulatory Factor 8 Regulates MDM2 in Germinal Center B Cells
Jeff X. Zhou et al.
JOURNAL OF IMMUNOLOGY (2009)
IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells
Babak Baban et al.
JOURNAL OF IMMUNOLOGY (2009)
CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia
Wei Xu et al.
LEUKEMIA RESEARCH (2009)
Crosstalk between adenosine receptor (A2A isoform) and ERα mediates ethanol action in MCF-7 breast cancer cells
Nicolas Etique et al.
ONCOLOGY REPORTS (2009)
Inhibition of JNK Enhances TGF-beta 1-Activated Smad2 Signaling in Mouse Embryonic Lung
Shu Wu et al.
PEDIATRIC RESEARCH (2009)
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Takeshi Azuma et al.
BLOOD (2008)
Adenosine receptors in regulation of dendritic cell differentiation and function
Sergey V. Novitskiy et al.
BLOOD (2008)
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape
Jessica B. Katz et al.
IMMUNOLOGICAL REVIEWS (2008)
Gene delivery of indoleamine 2,3-dioxygenase prolongs cardiac allograft survival by shaping the types of T-cell responses
Guang Yu et al.
JOURNAL OF GENE MEDICINE (2008)
Dual role of CD38 in microglial activation and activation-induced cell death
Lior Mayo et al.
JOURNAL OF IMMUNOLOGY (2008)
Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection
Agnes Witkiewicz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
FGF acts as a co-transmitter through adenosine A2A receptor to regulate synaptic plasticity
Marc Flajolet et al.
NATURE NEUROSCIENCE (2008)
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Fabio Malavasi et al.
PHYSIOLOGICAL REVIEWS (2008)
Suppression of p53-dependent senescence by the JNK signal transduction pathway
Madhurnita Das et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
Silvia Deaglio et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells
Antonio Curti et al.
BLOOD (2007)
Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes
Deepa R. Hammaker et al.
ARTHRITIS RESEARCH & THERAPY (2007)
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells
Francesca Fallarino et al.
JOURNAL OF IMMUNOLOGY (2006)
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host
B Huang et al.
CANCER RESEARCH (2006)
IFN-γ production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo
B Sawitzki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
DH Munn et al.
IMMUNITY (2005)
Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1:: Increased susceptibility to autoimmune disease
T Nishibori et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis
MI Koukourakis et al.
BRITISH JOURNAL OF CANCER (2003)
Interferon γ is required for activation-induced death of T lymphocytes
Y Refaeli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells
S Merighi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2002)
IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway
S Fulda et al.
ONCOGENE (2002)
Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells
S Deaglio et al.
BLOOD (2002)
Interferon γ stabilizes the T helper cell type 1 phenotype
YK Zhang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Share Paper
